ArticleProceedings (Baylor University. Medical Center)2025
Outcomes following ventricular tachycardia ablation in patients with end-stage kidney disease: US Renal Data System-based outcome data.
Article in Proceedings (Baylor University. Medical Center), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ventricular tachycardia in end-stage kidney disease.Proceedings (Baylor University. Medical Center) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Data on the outcomes of ablation for paroxysmal ventricular tachycardia (VT) in patients with end-stage renal disease (ESRD) are lacking. This study aimed to identify outcomes of ablation in ESRD patients admitted with paroxysmal VT using the United States Renal Data System (USRDS). Method: All ESRD adult patients who were hospitalized with paroxysmal VT were included from the USRDS registry. Patients were stratified based on ablation treatment. Baseline characteristics were compared using descriptive statistics, and time-to-event analysis was done with a Kaplan-Meier curve. Cox regression analysis was used to assess hazard ratio (HR) for predictors of mortality. Results: A total of 8116 patients were identified. Of them, 688 [8.5%] received a VT ablation. Patients in the ablation group were more frequently younger and of African American descent compared to the no ablation group. VT ablation patients had a higher number of hospitalizations. Both groups had a 5-year mortality >75%; patients in the ablation group had a lower 5-year mortality rate ( Conclusion: In selected patients with ESRD and paroxysmal VT, 5-year mortality was lower in those who received an ablation compared to no ablation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.